drug_type
RELEVANT_DRUG
intervention_type
Biologic immunotherapy (bispecific TCR–anti‑CD3 T‑cell engager)
drug_description
Tebentafusp (IMCgp100) is a bispecific ImmTAC T‑cell engager with an affinity‑enhanced TCR that binds the gp100 (PMEL) peptide presented by HLA‑A*02:01 on melanoma cells and an anti‑CD3 domain that recruits and activates T cells, inducing TCR/CD3 signaling, cytokine release, immune synapse formation, and tumor cell lysis.
nci_thesaurus_concept_id
C94208
nci_thesaurus_preferred_term
Tebentafusp
nci_thesaurus_definition
A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of tebentafusp into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells.
drug_mesh_term
Tebentafusp
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
A soluble ImmTAC that uses an affinity‑enhanced TCR to bind the gp100 (PMEL) peptide presented by HLA‑A*02:01 on melanoma cells and an anti‑CD3 domain to recruit and activate polyclonal T cells, crosslinking tumor cells and T cells to trigger TCR/CD3 signaling, cytokine release, immune synapse formation, and cytotoxic killing of gp100‑expressing tumor cells.
drug_name
Tebentafusp
nct_id_drug_ref
NCT06246149